Covid-19 roundup: No­vavax be­gins PhII tri­al in US and Aus­tralia; As­traZeneca signs US man­u­fac­tur­ing deal with Catal­ent

No­vavax is push­ing for­ward with the Phase II por­tion of a Phase I/II tri­al for its vac­cine in the US and Aus­tralia — this time putting the fo­cus on old­er pa­tients.

About 50% of par­tic­i­pants en­rolled in the Phase II por­tion are be­tween the ages of 60 to 84, ac­cord­ing to the US-based com­pa­ny. No­vavax re­cent­ly wrapped up the Phase I por­tion in Aus­tralia, and re­port­ed in a preprint that the can­di­date, NVX-CoV2373, elicit­ed an­ti­body re­spons­es greater than those seen in con­va­les­cent sera.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER